ReviewTherapeutic advances in vaccines2014
Killed oral cholera vaccines: history, development and implementation challenges.
Review in Therapeutic advances in vaccines, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Oral killed cholera vaccines for preventing cholera.The Cochrane database of systematic reviews · 2024Pooled it
- Trends and burden of diarrhoeal diseases across India, 1990 - 2023: A systematic analysis from the global burden of disease study 2023.New microbes and new infections · 2026Article
- Immunomodulatory Role of Milk on Gut Microbiota: Implications for Enhancing Oral Vaccine Efficacy.Probiotics and antimicrobial proteins · 2026Review
- Oral Cholera Vaccines as Transmission-Interrupting Tools for Cholera Control: A Narrative Review.Infection and drug resistance · 2026Review
- Recent epidemiological and management approaches for cholera in India.Proceedings (Baylor University. Medical Center) · 2026Review
- Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990-2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021.The Lancet. Infectious diseases · 2025Article
- Cholera rages in Africa and the Middle East: A narrative review on challenges and solutions.Health science reports · 2024Review
- Cholera resurgence in Africa: assessing progress, challenges, and public health response towards the 2030 global elimination target.Le infezioni in medicina · 2024Review
- Article
- Intracellular Expression of CTB inJournal of microbiology and biotechnology · 2023Article
- The Integrated Consideration of Vaccine Platforms, Adjuvants, and Delivery Routes for Successful Vaccine Development.Vaccines · 2023Review
- A scoping review of facilitators and barriers influencing the implementation of surveillance and oral cholera vaccine interventions for cholera control in lower- and middle-income countries.BMC public health · 2023Article
- InactivatedJournal of microbiology and biotechnology · 2022Article
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- Diagnosis, Management, and Future Control of Cholera.Clinical microbiology reviews · 2022Review
- Vaccination against Bacterial Infections: Challenges, Progress, and New Approaches with a Focus on Intracellular Bacteria.Vaccines · 2022Review
- Non-Canonical Host Intracellular Niche Links to New Antimicrobial Resistance Mechanism.Pathogens (Basel, Switzerland) · 2022Review
- Challenges for Programmatic Implementation of Oral Cholera Vaccine in India.The Journal of infectious diseases · 2021Article
- Investigation of perceived fear of COVID-19 and vaccine hesitancy in nursing students.Human vaccines & immunotherapeutics · 2021Article
- An Update on Cholera Immunity and Current and Future Cholera Vaccines.Tropical medicine and infectious disease · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholera is still a major global health problem, affecting mainly people living in unsanitary conditions and who are at risk for outbreaks of cholera. During the past decade, outbreaks are increasingly reported from more countries. From the early killed oral cholera vaccine, rapid improvements in vaccine development occurred as a result of a better understanding of the epidemiology of the disease, pathogenesis of cholera infection and immunity. The newer-generation oral killed cholera vaccines have been shown to be safe and effective in field trials conducted in cholera endemic areas. Likewise, they have been shown to be protective when used during outbreak settings. Aside from providing direct protection to vaccinated individuals, recent studies have demonstrated that these killed oral vaccines also confer indirect protection through herd immunity. Although new-generation oral cholera vaccines should not be considered in isolation from other preventive approaches in countries where they are most needed, especially improved water quality and sanitation, these vaccines serve as immediately available public health tools for preventing further morbidity and mortality from cholera. However, despite its availability for more than two decades, use of these vaccines has not been optimized. Although there are limitations of the currently available oral cholera vaccines, recent data show that the vaccines are safe, feasible to use even in difficult circumstances and able to provide protection in various settings. Clear identification of the areas and target population groups who will benefit from the use of the cholera vaccines will be required and strategies to facilitate accessibility and usage of these vaccines in these areas and population groups will need to be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.